文献速递血管炎

ANCA相关性血管炎随机试验结局指标的使用与报告:系统文献综述

Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review.
PubMed 文献 · Semin Arthritis Rheum · 2020-09-29

该系统综述检索Medline、Cochrane CENTRAL和ClinicalTrials.gov至2019年4月30日,纳入68项ANCA相关性血管炎随机对照试验,分析其结局指标的使用与报告情况。结果显示疾病活动度是最常评估的领域(98%),BVAS为最常用工具,但缓解和复发的定义及评估时间点存在异质性;患者报告结局和损伤指标常被遗漏。

要点

  • 疾病活动度在98%的随机试验中作为结局领域,BVAS是最常用工具。
  • 缓解和复发的定义及评估时间点(3、6、12个月最常见)存在显著异质性。
  • 患者报告结局(41%)和损伤指标(44%)在ANCA相关性血管炎试验中常被遗漏。

核心结论

  • ANCA相关性血管炎随机试验常用血管炎特异性工具评估疾病,但终点定义和评估时间点异质性大,患者报告结局和损伤指标常被遗漏。

研究设计与样本

  • 系统文献综述,检索Medline、Cochrane CENTRAL和ClinicalTrials.gov从建库至2019年4月30日,纳入68项入组肉芽肿性多血管炎和/或显微镜下多血管炎的随机对照试验。

主要发现

  • 疾病活动度在67项(98%)随机试验中作为结局领域被收集。
  • BVAS是疾病评估最广泛使用的工具,但缓解和复发的定义因主要终点定义而异。
  • 损伤(最常用血管炎损伤指数)在30项(44%)随机试验中作为结局。
  • 死亡率在26项(38%)研究中被指定为结局。
  • 患者报告结局在28项(41%)、药物暴露/安全性在58项(85%)、生物标志物在24项(35%)随机试验中被评估。

关键数值与推荐

  • 结局评估时间点差异显著,3、6或12个月为最常见时间点。

临床怎么用

  • 解读ANCA相关性血管炎试验时需注意缓解和复发定义及评估时间点的异质性,并关注患者报告结局和损伤指标是否被纳入。

局限性

  • 检索截止至2019年4月30日,未涵盖此后发表的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A comprehensive review of outcome measures used in randomized controlled trials (RCTs) of ANCA-associated vasculitis (AAV) could advance trial conductance for this disease. METHODS: A systematic literature review of outcome measures (as specified in methods section as primary and/or secondary outcomes) in RCTs of AAV was conducted. Medline, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception until April 30, 2019 for RCTs enrolling patients with granulomatosis with polyangiitis and/or microscopic polyangiitis. Outcome measures were organized according to domains (e.g. disease activity) and instruments [e.g. Birmingham Vasculitis Activity Score (BVAS)]. RESULTS: Out of 1101 identified records, 68 RCTs were eligible. Disease activity was an outcome domain collected in 67 (98%) of the RCTs. The BVAS was the most widely used instrument for disease assessment but definitions for remissions and relapse varied for the purpose of primary endpoint definitions. Damage, most often assessed by the Vasculitis Damage Index, was an outcome in 30 (44%) of the RCTs. Mortality was specified as an outcome in 26 (38%) studies. The following outcome domains were assessed: patient-reported outcomes (PROs) in 28 (41%), drug exposure/safety in 58 (85%), and biomarkers [acute phase reactants, ANCA levels] in 24 (35%). Timing for outcome assessment differed substantially, with 3, 6, or 12 months being the most frequent time points. CONCLUSION: Outcome measures used in trials in AAV commonly included vasculitis-specific tools for disease assessment, but with heterogeneity in endpoint-definitions and timing of assessments. Other core outcomes in AAV, including PROs, and damage measures, are often omitted in AAV trials.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Monti S, Quinn KA, Christensen R, et al. Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Semin Arthritis Rheum. 2020. PMID: 33130459. doi:10.1016/j.semarthrit.2020.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。